Business Standard

US accuses India of WTO rules violation over Nexavar: Report

Read more on:    News | Law | Natco Pharma | Anand Sharma
Related News

Citing testimony before Congress by US Patent and Trademark Office Deputy Director Teresa Stanek Rea, Huffington Post said: "Rea repeatedly castigated India's government for approving the generic drug, calling the move an 'agregious' violation of World Trade Organisation treaties."

The report further added, Rea stated she was "dismayed and surprised" by India's decision, while "she boasted about 'personally' engaging 'various agencies of the Indian government' in efforts to overturn in."

According to the report, Rea's testimony came under attack from NGOs.

"This is unprecedented, really shocking testimony," the Huffington Post post quoted the US manager of Doctors Without Borders Access to Medicines Campaign, Judit Rius.

In March this year, for the first time India had invoked a permitting Hyderabad-based to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.

Under compulsory licensing, the government had allowed Natco to sell the drug at a price not exceeding Rs 8,880 for a pack of 120 tablets required for a month's treatment as compared to a whopping Rs 2.80 lakh per month charged by Bayer for its patented Nexavar drug.

The government had defended the move, with Commerce and Industry Minister stating that India did not violate any WTO norms.

  

Read more on:   
|
|
|

Read More

Pak holds talks with ISAF to prevent cross-border attacks

Pakistan today said it is holding talks with the International Security Assistance Force in Afghanistan, including through a border coordination ...

Quick Links

Back to Top